Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $19

Author: Benzinga Newsdesk | April 18, 2024 09:19am
Scotiabank analyst George Farmer maintains Sage Therapeutics (NASDAQ:SAGE) with a Sector Outperform and lowers the price target from $34 to $19.

Posted In: SAGE

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist